Financial Health | Discover Wave's financial landscape, balancing a healthy current ratio against rapid cash burn, as it navigates critical development stages in the biotech secto |
Market Positioning | Learn how Wave aims to differentiate itself in competitive markets through less frequent dosing and novel mechanisms, with analyst price targets ranging from $9 to $36 |
Clinical Milestones | Delve into Wave's pipeline progress, with key data readouts expected in 2025 for AATD and obesity programs, potentially validating its RNA editing platform |
RNA Editing Pionee | Explore Wave Life Sciences' innovative approach to genetic medicine, leveraging RNA editing technology for potential breakthroughs in AATD, obesity, and other disorders |
Metrics to compare | WVE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipWVEPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.2x | −6.7x | −0.4x | |
PEG Ratio | 0.15 | 0.39 | 0.00 | |
Price / Book | 1.9x | 1.9x | 2.6x | |
Price / LTM Sales | 13.1x | 27.6x | 3.0x | |
Upside (Analyst Target) | 326.0% | 68.0% | 54.5% | |
Fair Value Upside | Unlock | −3.7% | 7.2% | Unlock |
Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington’s disease, as well as various preclinical programs utilizing its RNA medicines platform. Wave Life Sciences, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts.